NEW YORK (GenomeWeb) – Protea Biosciences and InSphero today said they will combine their 3D technologies into new products and services to be marketed to the pharmaceutical and biotechnology markets.

The collaboration will use Protea's proprietary LAESI direct molecular imaging platform to analyze InSphero's 3D InSight microtissues, resulting in 3D molecular profiles for tissue characterization, drug metabolism and distribution, pharmacokinetic, and toxicity applications, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.